case_images: PMC6421719_01
case_images: Restaging CT prior to Nivolumab. Image on the top shows the RLL at its largest diameter and the image on the bottom shows the LLL at its largest diameter.
case_images: CRIONM2019-8356148.001.jpg
case_images: PMC6421719_01_CRIONM2019-8356148.001.jpg
case_images: fig1
case_images: After 3 cycles of chemotherapy, her restaging CT showed an increase in size of the nodular lesion of RLL measuring 3.8 x 3.5 cm with LLL measuring 5.3 x 3.5 x 5.9 cm and subaortic node of 9 mm (Figure 1).
case_images: Restaging CT post 9 cycles of Nivolumab. There was a reduction of the RLL mass post 9 cycles of Nivolumab.
case_images: CRIONM2019-8356148.002.jpg
case_images: PMC6421719_01_CRIONM2019-8356148.002.jpg
case_images: fig2
case_images: A restaging scan after 9 cycles of Nivolumab in September 2016 showed some reduction in the RLL mass measuring 3.1 x 2.8 cm, an increase in LLL lesion 4.3 x 3.9 cm (Figure 2).
case_images: Restaging CT post 15 cycles of Nivolumab. Image on the top shows some reduction in RLL mass and the image on the bottom shows that the LLL mass had increased significantly.
case_images: CRIONM2019-8356148.003.jpg
case_images: PMC6421719_01_CRIONM2019-8356148.003.jpg
case_images: fig3
case_images: Stable pleural thickening is shown in Figure 3.
case_images: Restaging CT post 19 cycles of Nivolumab. There was a tumour regression in the RLL and LLL mass.
case_images: CRIONM2019-8356148.004.jpg
case_images: PMC6421719_01_CRIONM2019-8356148.004.jpg
case_images: fig4
case_images: The mass in the RLL also showed a reduction in size measuring 2.1 x 2.0 cm in maximum axial diameter (Figure 4).